Singapore: China Health Resource (CHRI) has developed a revolutionary TCM migraine medication called Toufeng Migraine tablet, which demonstrated an effective rate of 96.5 percent in clinical observations. The new product was developed utilizing the company's Dahurian Angelica (DAR) as one it's key ingredients.

According to the company's forecast, the world's major pharmaceutical markets for anti-migraine drug sales, including the US, France, Germany, Italy, Spain, Britain and Japan, will witness a growth from $2.86 billion in 2002 to over $5.6 billion by 2013. Unlike Toufeng Migraine tables, most available medications are pain killers and many have serious side effects or carry a risk of dependency and addiction.

Mr Jiayin Wang, chairman and CEO, CHRI, said that, "Toufeng Migraine tablets have proven effective in our tests. It is naturally derived from our trademarked Sichuan DAR. This new product has a strong export market demand with a potential for immeasurable health benefits. We expect this to provide tremendous economic growth for CHRI."

CHRI, which issued a final termsheet last month in an attempt to acquire Herborium, is now moving forward with the approval process world-wide and is working to develop and expand commercialization through strategic partnerships.

According to international epidemiological surveys, the incidence of migraines world-wide is 8.4 percent-to-28 percent. In China, prevalence rate for migraine is 9.85 percent and the annual incidence rate is 7.97 percent. With China's population of 1.3 billion, this percentage translates to 103.6 million people.

"The company is committed to the development and commercialization of effective, innovative and natural health solutions. We are very pleased with this new development of Toufeng tablets," added Mr Wang.